These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26089395)

  • 1. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
    Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
    Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
    Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
    Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
    Psatha N; Sgouramali E; Gkountis A; Siametis A; Baliakas P; Constantinou V; Athanasiou E; Arsenakis M; Anagnostopoulos A; Papayannopoulou T; Stamatoyannopoulos G; Yannaki E
    Hum Gene Ther Methods; 2014 Dec; 25(6):317-27. PubMed ID: 25333506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
    Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
    Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.
    Boulad F; Wang X; Qu J; Taylor C; Ferro L; Karponi G; Bartido S; Giardina P; Heller G; Prockop SE; Maggio A; Sadelain M; Rivière I
    Blood; 2014 Mar; 123(10):1483-6. PubMed ID: 24429337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
    Yannaki E; Papayannopoulou T; Jonlin E; Zervou F; Karponi G; Xagorari A; Becker P; Psatha N; Batsis I; Kaloyannidis P; Tahynopoulou V; Constantinou V; Bouinta A; Kotta K; Athanassiadou A; Anagnostopoulos A; Fassas A; Stamatoyannopoulos G
    Mol Ther; 2012 Jan; 20(1):230-8. PubMed ID: 21952171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined G-CSF and Plerixafor enhance hematopoietic recovery of CD34
    Arcangeli ML; Brault P; Bourhis JH; Kuhnowskie F; Henry E; Barroca V; Koscielny S; Pflumio F; Amsellem S
    Exp Hematol; 2020 Jun; 86():15-20.e2. PubMed ID: 32450206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
    Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
    Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
    Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
    Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.